Bevacizumab biosimilars market to reach $2.42 billion by 2030
The global bevacizumab biosimilars market is projected to rise from $1.64 billion in 2025 to $1.77 billion in 2026, driven by cancer prevalence, patent expirations and demand for lower-cost biologics. The Business Research Company says the market could grow to $2.42 billion by 2030 as biosimilar approvals, emerging-market adoption and oncology care shifts accelerate.
Why it matters: - Bevacizumab biosimilars are gaining traction as lower-cost alternatives in cancer care, where access to effective biologic therapies remains a major issue. - The market’s growth reflects rising global cancer incidence and broader pressure on health systems to expand treatment options without increasing costs. - The category matters most in cancers such as advanced non-small cell lung cancer and metastatic colorectal cancer.
What happened: - The Business Research Company released its report, Bevacizumab Biosimilars Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the market will rise from $1.64 billion in 2025 to $1.77 billion in 2026. - That 2025-to-2026 growth implies a 7.5% compound annual growth rate. - The report projects the market will reach $2.42 billion by 2030, at an 8.2% CAGR. - North America held the largest market share in 2025.
The details: - Bevacizumab biosimilars are designed to closely resemble the reference biologic bevacizumab. - These drugs work by blocking the formation of new blood vessels in tumors, which helps slow tumor growth and progression. - The report links near-term growth to patent expiration for the original bevacizumab drug, rising cancer cases, demand for cost-effective biologics, government support and advances in recombinant DNA technology. - Longer-term growth is tied to more biosimilar approvals, expansion in emerging markets, use of artificial intelligence in drug development, a shift toward outpatient oncology care and strategic partnerships among pharmaceutical companies. - The report highlights wider biosimilar use in cancer treatment, more cost-efficient therapies, expanded regulatory acceptance, growth in hospital and retail pharmacy networks and more specialized cancer treatment centers as key trends. - NHS England reported 354,820 new cancer cases in England in 2023, up 8,605 from 2022. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated graphics and tables. - The report offers a free sample and full report through the company’s sample request page and the full market report.
Between the lines: - The forecast suggests biosimilars are moving from a cost-saving option to a mainstream oncology growth category. - North America’s lead likely reflects stronger reimbursement, regulatory clarity and higher diagnosed cancer volumes. - The emphasis on AI, outpatient care and pharmacy-channel expansion suggests the market is becoming more operationally sophisticated, not just larger.
What's next: - The market is expected to keep expanding as more biosimilars enter approval pipelines and broader oncology adoption continues. - Competitive pressure should increase as manufacturers push into emerging markets and health systems look for cheaper biologic options. - The company says its 2026 market reports now include expanded strategic intelligence tools for buyers and investors.
The bottom line: - Bevacizumab biosimilars are set for steady double-digit-style expansion over the next several years as cancer incidence rises and health systems keep shifting toward lower-cost biologic alternatives.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Middle East Political Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.